Humacyte Inc (NASDAQ: HUMA) on Friday, plunged -2.55% from the previous trading day, before settling in for the closing price of $1.57. Within the past 52 weeks, HUMA’s price has moved between $1.15 and $9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 39.23%. With a float of $125.77 million, this company’s outstanding shares have now reached $130.03 million.
The firm has a total of 220 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of -1582.71%, and the pretax margin is 0.0%.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 18.87%, while institutional ownership is 27.76%. The most recent insider transaction that took place on Apr 08 ’25, was worth 66,000. In this transaction Director of this company bought 50,000 shares at a rate of $1.32, taking the stock ownership to the 91,207 shares. Before that another transaction happened on Apr 08 ’25, when Company’s Director bought 6,000 for $1.29, making the entire transaction worth $7,740. This insider now owns 8,400 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.23% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 2.40 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Analysing the last 5-days average volume posted by the [Humacyte Inc, HUMA], we can find that recorded value of 5.54 million was better than the volume posted last year of 3.48 million. As of the previous 9 days, the stock’s Stochastic %D was 53.43%. Additionally, its Average True Range was 0.27.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 6.76%, which indicates a significant decrease from 19.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 208.91% in the past 14 days, which was higher than the 121.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.0008, while its 200-day Moving Average is $4.9555. Now, the first resistance to watch is $1.6067. This is followed by the second major resistance level at $1.6833. The third major resistance level sits at $1.7467. If the price goes on to break the first support level at $1.4667, it is likely to go to the next support level at $1.4033. Now, if the price goes above the second support level, the third support stands at $1.3267.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 237.33 million based on 155,119K outstanding shares. Right now, sales total 0 K and income totals -148,700 K. The company made 0 K in profit during its latest quarter, and -20,940 K in sales during its previous quarter.
